ProLynx Issues U.S. Patent Covering Controlled Release Drug Conjugates
6/18/2014 9:06:37 AM
SAN FRANCISCO, June 17, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today announced that the United States Patent and Trademark Office has issued US Patent 8,754,190 entitled "Controlled Release from Macromolecular Conjugates".
Help employers find you! Check out all the jobs and post your resume.
comments powered by